arcoris bio has secured CHF 6.3 million in seed funding to advance its innovative MUSE® biomarker detection platform, co-led by Ventura Ace and ZEISS Ventures.
Target Company Overview
arcoris bio is a Swiss company specializing in life sciences research tools and in vitro diagnostics. The company has recently raised CHF 6.3 million in seed funding to propel the further development and commercialization of its innovative biomarker detection technology known as MUSE®. This cutting-edge platform is designed to enable the simultaneous detection of multiple biomarkers with exceptional sensitivity, thus playing a significant role in advancing digital pathology.
Industry Overview in Switzerland
The life sciences industry in Switzerland is renowned for its robust research and development environment, fueled by a combination of public and private investment. With a strong presence of leading pharmaceutical and biotechnology companies, the country serves as a global hub for innovation in healthcare solutions. The growing demand for precision medicine and personalized diagnostics has catalyzed advancements in biomarker technologies, positioning Switzerland at the forefront of medical innovation.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Switzerland's supportive regulatory framework and favorable business environment further enhance its attractiveness for start-ups focusing on life sciences. Enhanced infrastructur
Similar Deals
Navus Ventures → Cultivated Biosciences
2024
Ventura Ace and ZEISS Ventures
invested in
arcoris bio
in 2025
in a Seed Stage deal
Disclosed details
Transaction Size: $6M